Rena Science

Basic Information

Stock Code
4889
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
February 2000
Listing Year
September 2021
Official Website
https://www.renascience.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Libraware, Heartseed, Iole, Intertrade, Data Section, G.C. Planning, AnGes, Nexela Pharma, Canvas, Kids Well Bio, Peptide Dream, SanBio, Helios, Perseus Proteomics, QualiPs, Takara Bio, Convano, Japan Tissue Engineering, Ureba Net Koukoku Sha Group

Overview

Rena Science is an emerging company founded in 2000 as a venture from Tohoku University, centering on the development of leukemia treatment drugs and conducting research and development in the fields of pharmaceuticals and medical devices.

Current Situation

Rena Science recorded net sales of 139 million yen in the fiscal year ended March 2022, continuing research and development investments despite operating and ordinary losses. Its main business is drug discovery research centered on leukemia treatments, strengthening its technological foundation through joint research agreements with Tohoku University. Management resources are heavily focused on R&D, with a compact workforce of 5 employees possessing advanced technological capabilities. Compared to competitors, its strength lies in the utilization of innovative small-molecule compounds from university origins, and it has expanded its funding base through stock listing. Moving forward, it views the expansion of domestic and international pharmaceutical markets as growth opportunities and is focusing on research in new areas such as aging suppression. Challenges include intensifying market competition and development risks, but it aims to differentiate through collaboration with Tohoku University and proprietary technologies, targeting mid- to long-term profitability and strengthening its business foundation.

Trivia

Interesting Facts

  • Startup founded by a professor from Tohoku University School of Medicine.
  • First Tohoku University-originated venture to list on Tokyo Stock Exchange Mothers.
  • One of the few Japanese companies specialized in leukemia treatment drug development.
  • Conducts advanced R&D with only 5 employees.
  • Multiple teams awarded in international contests in aging suppression field.
  • Extends university-originated drug discovery technology to medical device development.
  • Headquarters initially located in Yokohama, Kanagawa Prefecture.
  • Actively promoting commercialization of medical robots.
  • Founder's family holds significant shares as major shareholders.
  • Develops drug discovery platforms utilizing AI.
  • Early entry into COVID-19 treatment drug development.
  • High evaluations at academic societies through advanced treatment research.
  • Strengthened R&D funding base through Mothers listing.
  • Deep ties with medical and academic communities in Tohoku region.
  • Rare bio venture also handling medical IT services.

Hidden Connections

  • Established based on Tohoku University research outcomes, with intra-university technology transfer as the foundation of corporate growth.
  • The Miyata family, major shareholders, are the founding family deeply involved in management.
  • Active technology sharing with other pharmaceutical companies supported by Tohoku University Venture Partners.
  • Cases of collaboration with other Tohoku University-originated companies in medical device development.
  • Aging suppression research from X Prize wins linked with domestic and international medical institutions.
  • Tokyo Stock Exchange Mothers listing became a success model for regional university-originated ventures.
  • Receiving public funding domestically and internationally for COVID-19 treatment drug development.
  • Advancing technology partnerships with related companies in AI utilization for drug discovery.

Future Outlook

Growth Drivers

  • Global expansion of the anticancer drug market
  • Increasing demand in aging suppression and regenerative medicine
  • Heightened investment in university-originated bio ventures
  • Acceleration of AI and IT introduction in drug discovery research
  • Growing needs for blood disorder treatments amid aging society
  • Rapid increase in demand for clinical trial support services domestically and internationally
  • Technological innovation and market development in medical devices
  • Tailwinds from government bio-industry promotion policies
  • Expanding social interest in sustainable medical technology development
  • Strengthened market access through global partnerships
  • Enhanced patent strategy for proprietary small-molecule compounds

Strategic Goals

  • Achieve net sales exceeding 10 billion yen
  • Obtain approval for main treatment drugs domestically and internationally
  • Expand product lineup in medical device business
  • Initiate clinical applications of aging suppression research
  • Global rollout of drug discovery platforms
  • Strengthen internal R&D organization and human resource development
  • Establish and disclose sustainability management
  • Achieve stable revenue through diverse business portfolio
  • Secure top domestic share in clinical trial support services
  • Stabilize funding procurement through deepened relations with major shareholders

Business Segments

Drug Discovery Research Support

Overview
Provides comprehensive support for drug discovery research utilizing cutting-edge compounds and technologies.
Competitiveness
Strong collaboration and technological foundation with Tohoku University
Customers
  • Pharmaceutical companies
  • Bio ventures
  • University research institutions
  • Public research institutions
  • Medical institutions
Products
  • Small-molecule compound library
  • Efficacy evaluation services
  • Drug discovery support systems
  • Target validation
  • Data analysis tools

Clinical Trial and Testing Support

Overview
Delegates and supports clinical trial planning and execution from a medical institution perspective.
Competitiveness
Abundant know-how in clinical trial operations
Customers
  • Pharmaceutical companies
  • CRO (Clinical Research Organizations)
  • Medical institutions
  • Public health institutions
Products
  • Clinical trial coordination
  • Clinical trial data management
  • Monitoring services
  • Regulatory compliance support

Medical Device Development and Sales

Overview
Provides equipment to support efficiency and advancement in medical settings.
Competitiveness
Product development closely attuned to medical sites
Customers
  • Hospitals
  • Clinics
  • Testing institutions
  • Rehabilitation facilities
Products
  • Clinical testing equipment
  • Treatment support robots
  • Vital signs monitors
  • Imaging diagnostic devices

Drug Development Platform Provision

Overview
Provides IT platforms to streamline drug development.
Competitiveness
Fusion of advanced IT and bio expertise
Customers
  • Pharma ventures
  • Major pharmaceutical companies
  • Research institutions
Products
  • Drug discovery platform
  • Bioinformatics analysis tools
  • Data sharing systems

Regenerative Medicine Related Services

Overview
Provides related technologies and materials for regenerative medicine to accelerate R&D.
Competitiveness
High-precision technology support from university origins
Customers
  • Regenerative medicine companies
  • Biotech companies
  • Educational institutions
Products
  • Cell culture technology support
  • Regenerative medicine materials provision
  • Research reagents

Pharmaceutical Manufacturing Outsourcing (CDMO)

Overview
Undertakes pharmaceutical manufacturing and quality control to provide reliability.
Competitiveness
Flexible manufacturing setup and regulatory compliance capabilities
Customers
  • Bio ventures
  • Pharmaceutical companies
  • Research institutions
Products
  • Pharmaceutical manufacturing services
  • Quality control and testing
  • Process development support

IT Services for Medical and Drug Discovery

Overview
Provides services supporting medical sites and pharmaceutical development with IT.
Competitiveness
IT technology proficient in medical collaboration
Customers
  • Pharmaceutical companies
  • Medical institutions
  • Public institutions
Products
  • Clinical data management systems
  • Clinical trial support software
  • Analysis platforms

Research Materials Sales

Overview
Stable supply of materials and reagents necessary for R&D.
Competitiveness
Utilization of proprietary compound library
Customers
  • University labs
  • Bio ventures
  • Pharmaceutical company R&D departments
Products
  • Research reagents
  • Cell lines
  • Analytical chemicals

Regulatory Compliance Consulting

Overview
Specialized consulting to support compliance with pharmaceutical regulations, etc.
Competitiveness
Support by former pharmaceutical reviewers
Customers
  • Pharmaceutical companies
  • Development ventures
  • Medical institutions
Products
  • Drug approval application support
  • Quality management audits
  • Safety evaluation support

Academic Support Services

Overview
Services supporting academic activities and research promotion.
Competitiveness
Extensive network in the medical industry
Customers
  • Academic societies
  • Physician groups
  • Pharmaceutical companies
Products
  • Academic conference planning and operation
  • Research grant support
  • Information dissemination support

Bioinformatics

Overview
Provides solutions based on biological information analysis technology.
Competitiveness
Fusion of advanced analysis technology and drug discovery expertise
Customers
  • Bio ventures
  • Pharmaceutical companies
  • Research institutions
Products
  • Genome analysis tools
  • Drug design services
  • Data analysis outsourcing

Treatment Development Partnerships

Overview
Promotes joint research and business collaborations in treatment development.
Competitiveness
Open innovation promotion capabilities
Customers
  • Medical research institutions
  • Pharmaceutical companies
  • Universities
Products
  • Joint R&D
  • Technology licensing
  • Clinical trial support

Competitive Advantage

Strengths

  • Strong collaboration system with Tohoku University
  • Advanced small-molecule compound technology
  • Highly specialized researcher team
  • Advanced drug discovery research infrastructure
  • Funding procurement power through listing
  • Medical device development capabilities
  • Flexible clinical trial support system
  • Specialization in bio-pharmaceuticals
  • Rapid decision-making due to small size
  • Proprietary compound library
  • Product lineup specialized in treatment areas
  • Extensive international research network
  • High R&D investment ratio
  • Promising aging suppression research
  • Regulatory compliance by experts

Competitive Advantages

  • Differentiation through proprietary technologies leveraging university-originated basic research
  • Diversified business展開 combining various pharmaceuticals and medical devices
  • Trust secured through high-precision clinical trial support services
  • Development capabilities proposing cutting-edge medical devices to clinical sites
  • Flexible and rapid R&D process operations
  • Brand value as one of the few Tohoku University-originated ventures
  • Regulatory compliance capabilities leveraging high expertise
  • Stabilization of revenue base through multifaceted business展開
  • Continuous technological innovation through university collaboration
  • Responsiveness to market needs specialized in treatment fields
  • Provision of drug discovery platforms incorporating proprietary IT technologies
  • Solution capabilities on both medical devices and pharmaceuticals
  • High technological reliability by experienced researchers
  • Focus on ongoing development through regular funding procurement
  • Establishment of advanced manufacturing and quality control systems

Threats

  • High technical and regulatory risks in drug discovery development
  • Intensifying competition with major pharmaceutical companies
  • Risks of clinical trial failures and delays
  • Prolongation and uncertainty in drug approval reviews
  • Changes in R&D funding environment
  • Emergence of generic drugs and alternative treatments
  • High market entry barriers and strengthened regulations
  • Challenges and competitors in global expansion
  • Difficulties in talent acquisition and development
  • Impact of infectious disease outbreaks on research activities
  • Intensified price competition due to patent expirations
  • Concerns over obsolescence due to rapid advancements in medical technology

Innovations

2023: Discovery of Novel Mechanism of Action for Leukemia Treatment Drug

Overview
Successfully established a new treatment mechanism utilizing small-molecule compounds from Tohoku University.
Impact
Contributes to improved treatment efficacy and reduced side effects

2024: 6 Teams Win X Prize in Aging Suppression Research

Overview
Received high evaluation in a global research contest, accelerating technology establishment in aging suppression.
Impact
Strengthens corporate brand and R&D capabilities

2022: Commercialization of Treatment Support Robot Begins

Overview
Developed and launched robot devices for supporting operations in medical settings.
Impact
Contributes to medical efficiency and safety improvements

2023: IT Enhancement of Drug Discovery Platform

Overview
Developed bioinformatics tools with added AI analysis functions to improve drug discovery efficiency.
Impact
Improved speed of new candidate compound discovery

2021: Expansion of Clinical Data Management System Adoption

Overview
Introduced new systems to medical institutions to improve clinical trial quality and data reliability.
Impact
Improved clinical trial success rates and efficiency

2023: Development of Low-Environmental-Impact Pharmaceutical Manufacturing Technology

Overview
Initiated development of new technologies aimed at reducing waste and energy use in manufacturing processes.
Impact
Reduced environmental impact and costs

2022: Joint Development of COVID-19 Related Treatment Drugs

Overview
Participated in new pharmaceutical development projects for infectious diseases, creating new treatment candidates.
Impact
Diversification into infectious disease countermeasures

2024: Development of Aging-Related Biomarkers

Overview
R&D of new biomarker technologies capable of measuring aging suppression effects.
Impact
Promotes application to treatment drug development

2023: Establishment of High-Purity Chemical Synthesis Technology for Pharmaceuticals

Overview
Completed new synthesis technologies contributing to improved quality of pharmaceutical ingredients.
Impact
Stable product supply and quality improvement

2022: Introduction of Smart Clinical Trial Support Tools

Overview
Developed IT tools for clinical trial efficiency and adopted in multiple trials.
Impact
Shortened clinical trial periods and cost reductions

Sustainability

  • Promotion of low-environmental-impact manufacturing technologies
  • Energy-saving in R&D processes
  • Waste recycling rate improvement plans
  • Social contribution activities supporting regional medical care
  • Thorough compliance and ethical management
  • Workplace environment improvements promoting diversity
  • Technology co-creation through open innovation
  • Promotion of sustainable medical technology development
  • Efforts to ensure employee health and safety
  • Efficient utilization and management of environmental resources
  • Improved sustainability through strengthened academic research collaborations
  • Promotion of green procurement and supplier management